Press release
Treatment Resistant Depression Clinical Trials 2024: FDA Approvals, Medication, Treatment Market, Therapies, Mechanism of Action, Route of Administration, Companies by DelveInsight | Navitor Pharmaceuticals, Supernus Pharmaceuticals, Novartis, Relmada The
Treatment Resistant Depression Clinical Trials
"Treatment Resistant Depression Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Treatment Resistant Depression Market.
The Treatment Resistant Depression Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for sample report @ https://www.delveinsight.com/sample-request/treatment-resistant-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key takeaways from the Treatment Resistant Depression Pipeline Report:
• Treatment Resistant Depression Companies across the globe are diligently working toward developing novel Treatment Resistant Depression treatment therapies with a considerable amount of success over the years.
• Treatment Resistant Depression companies working in the treatment market are GH Research Ireland Limited, atai Therapeutics, Inc., Beckley Psytech Limited, COMPASS Pathways, Mapreg, Sound Pharmaceuticals, Jiangsu Hansoh Pharmaceutical, Merck Sharp & Dohme, Novartis, Denovo Biopharma LLC, COMPASS Pathways, Navitor Pharmaceuticals, Supernus Pharmaceuticals, Relmada Therapeutics, Beckley Psytech, COMPASS Pathways, Axsome Therapeutics, Celon Pharma, and others, are developing therapies for the Treatment Resistant Depression treatment
• Emerging Treatment Resistant Depression therapies in the different phases of clinical trials are- GH001, VLS-01-203 BU, BPL-003, Psilocybin, MAP4343, Ebselen, HS-10345, MK-1942, MIJ821, Liafensine, Psilocybin, NV5138, REL-1017, BPL-003, COMP360 (Psilocybin), AXS-05, FALKIERI (esketamine DPI), and others are expected to have a significant impact on the Treatment Resistant Depression market in the coming years.
• In April 2024, The US Food and Drug Administration (FDA) has given approval to Freedom Biosciences' investigational new drug (IND) application for FREE001, allowing the start of its Phase IIa clinical trial for the ketamine-based combination therapy aimed at treating treatment-resistant depression (TRD). The trial, named FREE001-TRD-201, is scheduled to begin in the first half of this year and marks a notable step forward in addressing the unmet needs of TRD patients. FREE001, the company's lead program, combines ketamine with temsirolimus and is being developed as an additional therapy for adults with TRD who have not responded sufficiently to at least two antidepressant treatments.
• In February 2023, COMPASS Pathways has commenced a Phase III clinical trial, a multicenter, randomized, double-blind, controlled study designed to explore the effectiveness, safety, and tolerance of two doses of COMP360 in individuals diagnosed with Treatment-resistant Depression. The main objective of this trial is to assess the change in MADRS (Montgomery-Åsberg Depression Rating Scale) total score from baseline, comparing COMP360 25 mg against COMP360 1 mg as the primary endpoint.
• In July 2022, Abbott has obtained approval from the United States Food and Drug Administration (FDA) to utilize its deep brain stimulation (DBS) device in treating individuals with treatment-resistant depression (TRD).
Treatment Resistant Depression Overview
Treatment-resistant depression (TRD) refers to a form of depression that does not adequately respond to multiple standard treatments. Individuals diagnosed with TRD continue to experience depressive symptoms despite having undergone various therapies, which might include different antidepressant medications, psychotherapy, or other standard treatments for depression.
Get a Free Sample PDF Report to know more about Treatment Resistant Depression Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/treatment-resistant-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Emerging Treatment Resistant Depression Drugs Under Different Phases of Clinical Development Include:
• GH001: GH Research Ireland Limited
• VLS-01-203 BU: atai Therapeutics, Inc.
• BPL-003: Beckley Psytech Limited
• Psilocybin: COMPASS Pathways
• MAP4343: Mapreg
• Ebselen: Sound Pharmaceuticals
• HS-10345: Jiangsu Hansoh Pharmaceutical
• MK-1942: Merck Sharp & Dohme
• MIJ821: Novartis
• Liafensine: Denovo Biopharma LLC
• Psilocybin: COMPASS Pathways
• NV5138: Navitor Pharmaceuticals/Supernus Pharmaceuticals
• REL-1017: Relmada Therapeutics
• BPL-003: Beckley Psytech
• COMP360 (Psilocybin): COMPASS Pathways
• AXS-05: Axsome Therapeutics
• FALKIERI (esketamine DPI): Celon Pharma
Treatment Resistant Depression Route of Administration
Treatment Resistant Depression pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type
Treatment Resistant Depression Molecule Type
Treatment Resistant Depression Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Treatment Resistant Depression Pipeline Therapeutics Assessment
• Treatment Resistant Depression Assessment by Product Type
• Treatment Resistant Depression By Stage and Product Type
• Treatment Resistant Depression Assessment by Route of Administration
• Treatment Resistant Depression By Stage and Route of Administration
• Treatment Resistant Depression Assessment by Molecule Type
• Treatment Resistant Depression by Stage and Molecule Type
DelveInsight's Treatment Resistant Depression Report covers around 25+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Treatment Resistant Depression product details are provided in the report. Download the Treatment Resistant Depression pipeline report to learn more about the emerging Treatment Resistant Depression therapies at:
https://www.delveinsight.com/sample-request/treatment-resistant-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key companies in the Treatment Resistant Depression Therapeutics Market include:
Key companies developing therapies for Treatment Resistant Depression are - Navitor Pharmaceuticals, Supernus Pharmaceuticals, Novartis, Relmada Therapeutics, Beckley Psytech, COMPASS Pathways, Axsome Therapeutics, Celon Pharma, and others.
Treatment Resistant Depression Pipeline Analysis:
The Treatment Resistant Depression pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Treatment Resistant Depression with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Treatment Resistant Depression Treatment.
• Treatment Resistant Depression key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Treatment Resistant Depression Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Treatment Resistant Depression market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Treatment Resistant Depression drugs and therapies-
https://www.delveinsight.com/sample-request/treatment-resistant-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Treatment Resistant Depression Pipeline Market Drivers
• Increasing Prevalence of Treatment Resistant Depression increase in Research and Developmental activities for the treatment of Treatment Resistant Depression are some of the important factors that are fueling the Treatment Resistant Depression Market.
Treatment Resistant Depression Pipeline Market Barriers
• However, side-effects associated with the treatment of Treatment Resistant Depression, poor management of Treatment Resistant Depression and other factors are creating obstacles in the Treatment Resistant Depression Market growth.
Scope of Treatment Resistant Depression Pipeline Drug Insight
• Coverage: Global
• Key Treatment Resistant Depression Companies: GH Research Ireland Limited, atai Therapeutics, Inc., Beckley Psytech Limited, COMPASS Pathways, Mapreg, Sound Pharmaceuticals, Jiangsu Hansoh Pharmaceutical, Merck Sharp & Dohme, Novartis, Denovo Biopharma LLC, COMPASS Pathways, Navitor Pharmaceuticals, Supernus Pharmaceuticals, Relmada Therapeutics, Beckley Psytech, COMPASS Pathways, Axsome Therapeutics, Celon Pharma, and others
• Key Treatment Resistant Depression Therapies: GH001, VLS-01-203 BU, BPL-003, Psilocybin, MAP4343, Ebselen, HS-10345, MK-1942, MIJ821, Liafensine, Psilocybin, NV5138, REL-1017, BPL-003, COMP360 (Psilocybin), AXS-05, FALKIERI (esketamine DPI), and others
• Treatment Resistant Depression Therapeutic Assessment: Treatment Resistant Depression current marketed and Treatment Resistant Depression emerging therapies
• Treatment Resistant Depression Market Dynamics: Treatment Resistant Depression market drivers and Treatment Resistant Depression market barriers
Request for Sample PDF Report for Treatment Resistant Depression Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/treatment-resistant-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Treatment Resistant Depression Report Introduction
2. Treatment Resistant Depression Executive Summary
3. Treatment Resistant Depression Overview
4. Treatment Resistant Depression- Analytical Perspective In-depth Commercial Assessment
5. Treatment Resistant Depression Pipeline Therapeutics
6. Treatment Resistant Depression Late Stage Products (Phase II/III)
7. Treatment Resistant Depression Mid Stage Products (Phase II)
8. Treatment Resistant Depression Early Stage Products (Phase I)
9. Treatment Resistant Depression Preclinical Stage Products
10. Treatment Resistant Depression Therapeutics Assessment
11. Treatment Resistant Depression Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Treatment Resistant Depression Key Companies
14. Treatment Resistant Depression Key Products
15. Treatment Resistant Depression Unmet Needs
16 . Treatment Resistant Depression Market Drivers and Barriers
17. Treatment Resistant Depression Future Perspectives and Conclusion
18. Treatment Resistant Depression Analyst Views
19. Appendix
20. About DelveInsight
Trending Reports:
• Wound Irrigation Systems Market: https://www.delveinsight.com/report-store/wound-irrigation-systems-market
• Chronic Bronchitis Market: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
• Ashermans Syndrome Market: https://www.delveinsight.com/sample-request/ashermans-syndrome-market
• Necrotizing Enterocolitis Market: https://www.delveinsight.com/report-store/necrotizing-enterocolitis-market
• Giant Papillary Conjunctivitis Market: https://www.delveinsight.com/report-store/giant-papillary-conjunctivitis-market
• Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Radioligand Therapies Market: https://www.delveinsight.com/report-store/radioligand-therapies-market-forecast
• Triple Negative Breast Cancer Market: https://www.delveinsight.com/report-store/triple-negative-breast-cancer-tnbc-market
• Chronic Obstructive Pulmonary Disease Copd Market: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
• Nsclc Market: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-market
• Post-bariatric Hypoglycemia Market: https://www.delveinsight.com/report-store/post-bariatric-hypoglycemia-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Acute On Chronic Liver Failure Aclf Market: https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market
• Acute Radiation Syndrome Market: https://www.delveinsight.com/report-store/acute-radiation-syndrome-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Bipolar Depression Market: https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Scleroderma Market: https://www.delveinsight.com/report-store/scleroderma-market
• Acquired Immunodeficiency Syndrome Market: https://www.delveinsight.com/report-store/acquired-immunodeficiency-syndrome-aids-market
• Acute Pharyngitis Market: https://www.delveinsight.com/report-store/acute-pharyngitis-market
• Alport Syndrome Market: https://www.delveinsight.com/report-store/alport-syndrome-market
• Beta Thalassemia Market: https://www.delveinsight.com/report-store/beta-thalassemia-market
• Cardiotoxicity Market: https://www.delveinsight.com/report-store/cardiotoxicity-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Primary Progressive Multiple Sclerosis Ppms Market: https://www.delveinsight.com/report-store/primary-progressive-multiple-sclerosis-ppms-pipeline-insight
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/conference-coverage-services
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Treatment Resistant Depression Clinical Trials 2024: FDA Approvals, Medication, Treatment Market, Therapies, Mechanism of Action, Route of Administration, Companies by DelveInsight | Navitor Pharmaceuticals, Supernus Pharmaceuticals, Novartis, Relmada The here
News-ID: 3696326 • Views: …
More Releases from DelveInsight Business Research
Bardet-Biedl Syndrome Market Outlook 2034 - Clinical Trials, Market Size, Medica …
DelveInsight's recent publication, "Bardet-Biedl Syndrome Market Insight, Epidemiology, and Market Forecast - 2034," delivers an exhaustive examination of the evolving therapeutic and diagnostic landscape of this rare condition.
The report encompasses major markets, including the United States, the EU4 nations (Germany, France, Italy, Spain), the United Kingdom, and Japan. It highlights existing shortcomings in diagnostic capabilities and therapeutic options while providing insights into emerging strategies designed to improve management of Bardet-Biedl…
Global GM2 Gangliosidosis Clinical Trials 2025: Drug Pipeline, Regulatory Approv …
DelveInsight's "GM2 Gangliosidosis - Pipeline Insight, 2025" delivers an in-depth evaluation of the global research and development landscape, profiling both clinical and preclinical drug candidates with varied mechanisms of action. The report explores key advancements including AAV-based gene therapies focused on the central nervous system, innovations in delivery technologies, and novel approaches aimed at improving long-term safety and efficacy. It also examines shifting regulatory frameworks, biomarker-guided clinical trial designs, and…
Global Basal Cell Nevus Syndrome Clinical Trials 2025: Drug Pipeline, Regulatory …
DelveInsight's "Basal Cell Nevus Syndrome (BCNS) - Pipeline Insight, 2025" provides an in-depth analysis of both current and forthcoming treatment options. The report covers therapies in clinical and preclinical stages, highlights innovative drug delivery technologies, and examines efforts to tailor treatments through genetic profiling. It also reviews regulatory advancements, rare disease designations, and key collaborations driving progress in this specialized yet critical area.
As the pipeline advances, a shift from managing…
Global Cerebral Amyloid Angiopathy Clinical Trials 2025: Drug Pipeline, Regulato …
DelveInsight's "Cerebral Amyloid Angiopathy Pipeline Insight, 2025" provides an in-depth analysis of the current and emerging therapeutic landscape for Cerebral Amyloid Angiopathy (CAA). The report comprehensively profiles ongoing clinical and preclinical development programs targeting disease modification, evaluates investigational imaging biomarkers to enhance early and accurate diagnosis, and examines regulatory frameworks alongside translational research initiatives that are accelerating drug development in this historically under-recognized cerebrovascular disorder.
With increasing awareness of Cerebral Amyloid…
More Releases for Treatment
Trigeminal Neuralgia Treatment Market Size, Trigeminal Neuralgia Treatment Marke …
Trigeminal Neuralgia Treatment Market Dynamics are clarified by an in-depth review of facts on current and emerging trends. To understand a resource, the paper uses Porter's five forces to examine the importance of numerous qualities such as understanding of suppliers and customers, dangers provided by various agents, competitive strength, and promising new businesses. precious. Furthermore, the study covers numerous firms' Trigeminal Neuralgia Treatment research data, benefit, gross margin, worldwide market…
Medical Tourism Market Report by Treatment Type (Dental Treatment, Cosmetic Trea …
The global medical tourism market accounted for $104.68 billion in 2019, and is projected to reach $273.72 billion by 2027, registering a CAGR of 12.8% from 2019 to 2027 in terms of value.
View Full Report: https://reports.valuates.com/market-reports/ALLI-Auto-0P310/medical-tourism
In terms of volume, the global medical tourism market accounted for 23,042.90 thousand patients in 2019, and is projected to reach 70,358.61 thousand patients by 2027, registering a CAGR of 15.0% from 2019 to…
Stretch Marks Treatment Market by Treatment & Forecast - 2025
Global Stretch Marks Treatment Market: Snapshot
In order to expand their outreach and add to their product portfolio, keen players in the global stretch marks treatment market are taking the inorganic route of acquisitions. They are also pouring money into development of new and better products.
Rising instances of obesity causing stretch marks is serving to catalyze growth in the market. In addition, growing aesthetic consciousness among people, especially among pregnant women,…
Stretch Marks Treatment Market by Treatment & Forecast - 2025
Global Stretch Marks Treatment Market: Snapshot
In order to expand their outreach and add to their product portfolio, keen players in the global stretch marks treatment market are taking the inorganic route of acquisitions. They are also pouring money into development of new and better products.
Rising instances of obesity causing stretch marks is serving to catalyze growth in the market. In addition, growing aesthetic consciousness among people, especially among pregnant women,…
Medical Tourism Market by Treatment Type (Dental Treatment, Cosmetic Treatment, …
Medical Tourism Market Overview:
The global medical tourism market was valued at $53,768 million in 2017, and is estimated to reach at $143,461 million by 2025, registering a CAGR of 12.9% from 2018 to 2025.
Organized travel across international borders to avail medical treatment of some form, which may or may not be available in the travelers home country is defined as medical tourism. Medical tourists travel abroad for the maintenance, enhancement,…
Substance Use Disorder Treatment Market By Type (Alcohol abuse treatment, Nicoti …
According to World Health Organization (WHO), the leading cause of disability around the world is not a physical disease, but a serious mood disorder known as depression. Around 350 million people suffer from depression worldwide, and that only about 50% of these individuals will ever receive treatment. According to Anxiety and Depression Association of America, in the U.S., over 15 million adults experience an episode of clinical depression in any…
